Patents by Inventor Hui-Quan Han

Hui-Quan Han has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • The human E3alpha ubiquitin ligase family
    Publication number: 20070231831
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Application
    Filed: April 24, 2007
    Publication date: October 4, 2007
    Applicant: AMGEN INC.
    Inventors: Hui-Quan Han, Keith Kwak
  • Human E3? ubiquitin ligase family
    Patent number: 7220547
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: May 22, 2007
    Assignee: Amgen, Inc.
    Inventors: Hui-Quan Han, Keith Kwak
  • Human E3? ubiquitin ligase family
    Patent number: 7179625
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: February 20, 2007
    Assignee: Amgen Inc.
    Inventors: Hui-Quan Han, Keith Kwak
  • Human E3alpha ubiquitin ligase family
    Publication number: 20050089876
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3? ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Application
    Filed: January 15, 2004
    Publication date: April 28, 2005
    Inventors: Hui-Quan Han, Keith Kwak
  • Human E3alpha ubiquitin ligase family
    Publication number: 20040185037
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3&agr; ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Application
    Filed: January 15, 2004
    Publication date: September 23, 2004
    Inventors: Hui-Quan Han, Keith Kwak
  • Human E3&agr; ubiquitin ligase family
    Patent number: 6706505
    Abstract: The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3&agr; ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 16, 2004
    Assignee: Amgen Inc
    Inventors: Hui-Quan Han, Keith Kwak
  • Treatment of alzheimer disease by modulation of synapsins
    Patent number: 6444201
    Abstract: The role of synapsin II in both the reformation and the maintenance of synaptic connections in cultured hippocampal neurons can be the basis of therapy for neurodegenerative disorder, particularly Alzheimer disease, which involve the disruption of synapses. When synapsin II expression in neurons is blocked by antisense synapsin II oligonucleotides, the ability of hippocampal neurons to reform as well as to maintain synapses is severely disrupted. Antisense suppression of synapsin II after axon formation but immediately before synaptogenesis prevents synapse formation. Suppression of synapsin II after synaptogenesis disrupts the majority of existing synapses. Re-expression of synapsin II in synapsin deficient neurons achieved after removing the antisense oligonucleotides leads to the re-establishment of synaptic connections, providing direct evidence that synapsin II is required for the maintenance and/or restoration of synapses.
    Type: Grant
    Filed: May 13, 1996
    Date of Patent: September 3, 2002
    Assignees: The Rockefeller University, Brighan and Women's Hospital
    Inventors: Hui-Quan Han, Paul Greengard, Kenneth S. Kosik, Adriana Ferreira